Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on "Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients".
作者信息
Lee Hae Lim, Jang Jeong Won
机构信息
Division of Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
The Catholic University Liver Research Center, Seoul, Korea.
出版信息
Clin Mol Hepatol. 2024 Oct;30(4):692-694. doi: 10.3350/cmh.2024.0346. Epub 2024 May 14.
Abstract
摘要
相似文献
1
Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on "Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients".核心蛋白抑制剂：乙肝治愈前沿的机遇与挑战：关于“EDP-514在未经治疗的病毒血症慢性乙肝患者中的安全性、药代动力学及抗病毒活性的1期试验”的社论
Clin Mol Hepatol. 2024 Oct;30(4):692-694. doi: 10.3350/cmh.2024.0346. Epub 2024 May 14.
2
Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients.EDP-514 治疗未经治疗的病毒血症慢性乙型肝炎患者的安全性、药代动力学和抗病毒活性的 1 期临床试验。
Clin Mol Hepatol. 2024 Jul;30(3):375-387. doi: 10.3350/cmh.2023.0535. Epub 2024 Mar 26.
3
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B.EDP-514 在健康受试者和核苷（酸）逆转录酶抑制剂抑制的慢性乙型肝炎患者中的研究。
Antivir Ther. 2022 Dec;27(6):13596535221127848. doi: 10.1177/13596535221127848.
4
Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection.塞尔甘托利莫德在慢性乙型肝炎病毒感染病毒血症患者中的安全性、药效学及抗病毒活性
JHEP Rep. 2023 Nov 30;6(2):100975. doi: 10.1016/j.jhepr.2023.100975. eCollection 2024 Feb.
5
Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.乙型肝炎病毒核心抑制剂 ABI-H0731 的安全性、药代动力学和抗病毒作用：一项随机、安慰剂对照的 1 期临床试验。
Lancet Gastroenterol Hepatol. 2020 Feb;5(2):152-166. doi: 10.1016/S2468-1253(19)30346-2. Epub 2019 Nov 9.
6
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.在初治慢性乙型肝炎病毒感染患者中，韦比科韦与恩替卡韦联合使用的安全性和有效性。
J Hepatol. 2022 Nov;77(5):1265-1275. doi: 10.1016/j.jhep.2022.05.027. Epub 2022 Jun 11.
7
Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression.在病毒抑制的慢性乙型肝炎个体中口服 TLR8 激动剂 selgantolimod 的安全性和疗效。
J Hepatol. 2023 Mar;78(3):513-523. doi: 10.1016/j.jhep.2022.09.027. Epub 2022 Oct 29.
8
Safety, pharmacokinetics and antiviral activity of ABI-H2158, a hepatitis B virus core inhibitor: A randomized, placebo-controlled phase 1 study.ABI-H2158 治疗慢性乙型肝炎的安全性、药代动力学和抗病毒活性：一项随机、安慰剂对照的 1 期研究。
J Viral Hepat. 2023 Mar;30(3):209-222. doi: 10.1111/jvh.13764. Epub 2023 Jan 12.
9
[Antiviral therapy and clinical cure for chronic hepatitis B in children: progress and challenges].[儿童慢性乙型肝炎的抗病毒治疗与临床治愈：进展与挑战]
Zhonghua Gan Zang Bing Za Zhi. 2021 Dec 20;29(12):1218-1223. doi: 10.3760/cma.j.cn501113-20210628-00303.
10
HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure.HBsAg 消失作为慢性 HBV 感染的治疗终点：HBV 治愈。
Viruses. 2022 Mar 22;14(4):657. doi: 10.3390/v14040657.
本文引用的文献
1
Toward a Functional Cure for Hepatitis B.迈向乙型肝炎功能性治愈。
Gut Liver. 2024 Jul 15;18(4):593-601. doi: 10.5009/gnl240023. Epub 2024 Mar 27.
2
Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients.EDP-514 治疗未经治疗的病毒血症慢性乙型肝炎患者的安全性、药代动力学和抗病毒活性的 1 期临床试验。
Clin Mol Hepatol. 2024 Jul;30(3):375-387. doi: 10.3350/cmh.2023.0535. Epub 2024 Mar 26.
3
Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses.长期开放标签使用韦比科韦治疗慢性乙型肝炎病毒感染：安全性和停药后反应
JHEP Rep. 2024 Jan 18;6(4):100999. doi: 10.1016/j.jhepr.2023.100999. eCollection 2024 Apr.
4
Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.在初治慢性乙型肝炎病毒感染患者中，韦比科韦与恩替卡韦联合使用的安全性和有效性。
J Hepatol. 2022 Nov;77(5):1265-1275. doi: 10.1016/j.jhep.2022.05.027. Epub 2022 Jun 11.
5
Effect of Antiviral Treatment on Hepatitis B Virus Integration and Hepatocyte Clonal Expansion.抗病毒治疗对乙型肝炎病毒整合和肝细胞克隆扩增的影响。
Clin Infect Dis. 2023 Feb 8;76(3):e801-e809. doi: 10.1093/cid/ciac383.
6
Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection.韦柏ovir 在慢性乙型肝炎病毒感染病毒学抑制患者中的安全性和疗效。
J Hepatol. 2022 Sep;77(3):642-652. doi: 10.1016/j.jhep.2022.04.005. Epub 2022 Apr 20.
7
The potential immune regulation benefit of CpAMs beyond HBV suppression.除抑制乙肝病毒外，环戊酸类药物潜在的免疫调节益处。
Lancet Gastroenterol Hepatol. 2021 Sep;6(9):680-682. doi: 10.1016/S2468-1253(21)00256-9.
8
Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance.在乙型肝炎表面抗原血清学清除后发展为肝细胞癌的患者中，乙型肝炎病毒 DNA 整合的持续存在。
Clin Mol Hepatol. 2021 Jan;27(1):207-218. doi: 10.3350/cmh.2020.0115. Epub 2020 Dec 3.
9
Antiviral Properties and Mechanism of Action Studies of the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379.JNJ-56136379 作为乙型肝炎病毒衣壳组装调节剂的抗病毒特性和作用机制研究。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.02439-19.
10
Discovery of Novel Hepatitis B Virus Nucleocapsid Assembly Inhibitors.新型乙型肝炎病毒核衣壳组装抑制剂的发现
ACS Infect Dis. 2019 May 10;5(5):759-768. doi: 10.1021/acsinfecdis.8b00269. Epub 2018 Dec 19.
Zotero 插件